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Background-—Isolation of the pulmonary veins (PVs) for the treatment of atrial ﬁbrillation (AF) is often supplemented with linear
lesions within the left atrium (LA). However, there are conﬂicting data on the effects of creating a roof line (RL) joining the superior
PVs in paroxysmal atrial ﬁbrillation (PAF).
Methods and Results-—A cohort of 120 patients with drug-refractory PAF referred for ablation were prospectively randomized into
2 strategies: (1) PV isolation in combination with RL ablation (LA roof ablation [LARA]-1: 59 patients) or (2) PV isolation (LARA-2: 61
patients). Follow-up was performed at 1, 3, and 6 months after the procedure and every 6 months thereafter. After a 3-month
blanking period, recurrence was deﬁned as the ocurrence of any atrial tachyarrhythmia lasting ≥30 seconds. PV isolation was
achieved in 89% and complete RL block in 81%. RF duration, ﬂuoroscopy, and procedural times were slightly, but not signiﬁcantly,
longer in the LARA-1 group. After 1510 months, there was no difference in the arrhythmia-free survival after a single AF ablation
procedure (LARA-1: 59% vs. LARA-2: 56% at 12 months; log rank P=0.77). The achievement of complete RL block did not inﬂuence
the results. The incidence of LA macroreentrant tachycardias was 5.1% in the LARA-1 group (n=3) versus 8.2% in the LARA-2 (n=5)
(P=ns). Univariate analysis only identiﬁed AF duration as a covariate associated with arrhythmia recurrence (hazard ratio, 1.01 [95%
conﬁdence interval, 1.002 to 1.012]; P<0.01).
Conclusion-—The linear block at the LA roof is not associated with an improved clinical outcome compared with PV isolation alone.
Clinical Trial Registration-—URL: ClinicalTrials.gov. Unique identiﬁer: NCT01203241. ( J Am Heart Assoc. 2014;3:e000877 doi:
10.1161/JAHA.114.000877)
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E lectrical isolation of the pulmonary veins (PVs) iscurrently the most commonly employed ablation strat-
egy for the treatment of paroxysmal atrial ﬁbrillation (PAF).1–4
However, in some patients, PV isolation may not be sufﬁcient
as a result of greater extension of atrial ﬁbrosis.5 For this
reason, the creation of additional linear lesions in the left
atrium (LA) has been proposed. These lines include the LA
“roof,” the posterior line, and the mitral isthmus.6–12
Still, the role of additional lines remains controversial. The
systematic isolation of the posterior wall does not seem to
achieve better results.13 In contrast, one single-centre
prospective randomized study suggests a better outcome
with the addition of the roof line (RL) in PAF.9
The aim of the present study is to assess whether the LA
roof ablation (LARA) adds any beneﬁt to the arrhythmia-free
probability after PAF ablation.
Methods
Between September 2009 and October 2011, 120 consecutive
patients admitted for a ﬁrst catheter ablation for symptomatic,
drug-refractory, paroxysmal PAF were prospectively included in
the study. Patients with any treatable cause of atrial ﬁbrillation
(AF), contraindication for anticoagulation or LA thrombus, LA
anteroposterior diameter >50 mm, moderate or severe mitral
valve disease, prosthetic mitral valve, and/or left ventricular
(LV) ejection fraction (LVEF) <30% were excluded (Figure 1).
The study protocol was approved by our hospital’s ethics
committee, and written informed consent was obtained from
all patients according to the Declaration of Helsinki Ethical
Principles for Medical Research Involving Human Subjects.
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Baseline Assessment
After written informed consent was obtained, a complete
clinical evaluation was performed (including physical exami-
nation, 12-lead electrocardiogram (ECG), and laboratory
exams). All patients underwent a transthoracic echocardio-
gram (TTE) 1 to 30 days before the procedure and a multislice
computed tomography (CT) or magnetic resonance (MR) to
image the LA and PV anatomy. Transesophageal echocardi-
ography was performed 24 to 48 hours before the procedure
in patients with indication for chronic oral anticoagulation
resulting from a high cardioembolic risk.14 In patients treated
with chronic oral anticoagulation, bridging with low-molecular-
weight heparin (LMWH) was used, which was interrupted
12 hours before the procedure.
Ablation Procedure
The procedure was performed under deep sedation. After dual
transseptal access, a bolus of intravenous heparin (50 UI/kg)
was administered, with additional boluses to maintain an
activated clotting time of >250 seconds and a 20-pole circular
mapping catheter (Lasso; BiosenseWebster, Diamond Bar, CA
or Inquiry Optima; St. Jude Medical, St. Paul, MN) was placed
at the PV ostium. Ablation was assisted by a three-dimensional
(3D) nonﬂuoroscopic mapping system (CARTO XP or CARTO
3; Biosense Webster or EnSite NavX; St. Jude Medical). For
accurate visualization of the PVs and other left atrial landmarks,
we used image integration of the electroanatomical map with
the anatomical information provided by CT or MR imaging
(obtained before the procedure) in all patients. Radiofrequency
(RF) was delivered by a 3.5-mm open-irrigation catheter at a
target temperature of 45°C and a maximum output of 40 W
(NaviStar or Celsius; Biosense Webster). In order to reduce
the risk of esophageal complications, power was reduced to
35 W in the posterior wall and RF application was limited to 10
to 20 seconds per point. For all other areas in the LA (including
the roof), a 40-W power limit was used.
Isolation of PVs was achieved by continuous circular
lesions around the venoatrial junction of ipsilateral PVs,
Figure 1. Consort ﬂow chart of the study population. LA indicates left atrium; LAVA, left atrial roof linear
ablation; LV, left ventricle.
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checking for bidirectional conduction block. An additional line
was performed at the carina between ipsilateral veins in case
of separate ostia.
After PV electrical isolation, patients were randomly
assigned to the 2 ablation strategies (Figure 2): (1) linear
ablation at the LA roof (LARA-1) or (2) no further ablation
(LARA-2). The RL ablation was performed at the most cranial
part of the LA, connecting the upper aspect of the right and
left PV encircling lesions. RF energy was delivered for 30 to
90 seconds at each point until local potential elimination or
double potentials were observed. Completeness of conduc-
tion block was conﬁrmed during LA appendage pacing by the
online mapping of continuous double potential and an
activation detour propagating around the PVs to activate
caudocraneally the posterior wall of the LA (Figure 3).9,15
When residual conduction was demonstrated, detailed map-
ping was performed to identify and ablate gaps in the linear
lesion.
All procedural endpoints were evaluated in sinus rhythm.
Electrical cardioversion was performed when necessary.
Postprocedural Management
After the procedure, a TTE was performed to rule out
pericardial effusion. Anticoagulation was started by LMWH
and acenocumarol afterward until an international normalized
ratio >2 was achieved, then maintained for 3 months in all
patients and according to the individual cardioembolic risk
score thereafter. Antiarrhythmic treatment was given to all
patients during the ﬁrst 3 months after the procedure:
A
B
Figure 2. Ablation strategy. A, PV isolation with roof linear ablation (LARA-1). B, PV isolation without
roof linear ablation (LARA-2). AP indicates anteroposterior; LAVA, left atrial roof linear ablation;
PA, posteroanterior; PV, pulmonary veins.
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ﬂecainide (100 mg BID) in the absence of structural heart
disease and amiodarone (200 mg QD) or sotalol (80 to
160 mg BID), if present. Afterward, antiarrhythmic drugs were
interrupted and only reintroduced if any arrhythmic event was
documented.
Follow-up
Follow-up was performed at the outpatient clinic at 1, 3, and
6 months after the procedure and every 6 months thereaf-
ter. Evaluation included assessment of arrhythmia-related
symptoms, adverse events, and treatment adherence and
any additional therapy since the previous follow-up visit.
Routine 48-hour Holter monitoring was performed before
each visit, and patients were asked to go to an emergency
department if any symptom suggestive of recurrence
occurred between scheduled visits. The minimum follow-up
of the study population was 6 months after the AF ablation
procedure.
Deﬁnitions
Arrhythmia recurrence is deﬁned as any arrhythmia of
≥30 seconds documented by an ECG or device recording
system, after a 3-month blanking period. Cavo-tricuspid
isthmus-dependent ﬂutter was not considered recurrence.
A blanking period of 3 months was employed after
ablation. Recurrences within these ﬁrst 3 months were not
classiﬁed as failure of the procedure. Any patient suffering a
persistent atrial arrhythmia during this period was reverted to
sinus rhythm by electrical cardioversion.
Statistical Analysis
The primary endpoint of the study was freedom from
arrhythmia recurrence after a single ablation procedure. Any
episode of AF or LA ﬂutter within the ﬁrst 3 months after the
procedure was considered part of the blanking period (not
recurrence). The ablation group was blinded to patients and to
the physicians evaluating the outcome of the procedure.
On the basis of our group’s experience, at 6-month follow-
up, we expected 55% of patients to be free of arrhythmia after
a single PV isolation procedure. With a sample size of 60
patients per arm, a log-rank test for equality of survival curves
will have 80% power and a 2-sided a-value of 0.05 to detect
an expected 20% reduction in freedom from arrhythmia in the
LARA-1 group. Randomization was performed according to a
computer-generated algorithm in blocks of 20 patients.
Inclusion was stopped once 120 patients were enrolled.
Continuous data are presented as the mean valueSD.
Qualitative variables are expressed as the number of cases
and percentages. To compare means of 2 variables within the
same group, we used the paired-samples Student t test.
Arrhythmia-free survival curves for each group were
compared by log-rank test and presented as Kaplan-Meier
plots. Cox’s method was used to estimate the effect of the LA
roof linear ablation after adjusting for baseline variables. The
following potential predictors of recurrence were considered:
age, sex, duration of AF, LA diameter, LV end-diastolic, and
end-systolic diameters, LVEF, hypertension, and structural
heart disease. The backward step-wise method with criteria of
P<0.10 for inclusion and P>0.10 for removal was used for the
ﬁnal model. A 2-sided probability value <5% (P<0.05) was
Figure 3. Evaluation of conduction block across the roof during pacing from the LA appendage (LAA).
A, Color-coded 3D activation map showing a caudocranial activation of the posterior wall. B, Electrical
activation showing shorter activation times at the lower (1: 72 ms) than at the upper posterior wall
(2: 98 ms). LA indicates left atrium.
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considered statistically signiﬁcant. Statistical analysis was
performed using R software (version 3.0.1; the R Project for
Statistical Computing, R Foundation for Statistical Computing,
Vienna, Austria).
Results
Baseline Characteristics and Procedural Data
One hundred and twenty patients were randomized for
analysis: 59 patients in the LARA-1 group and 61 patients
in the LARA-2 group (Figure 1). The mean age was 5511,
20% were older than 65 years, and 71% were males. A
previous history of stroke was noted in 0.8% of patients and
the CHA2DS2-VASc score was ≥1 in 52.5%. No signiﬁcant
baseline differences were observed between groups (Table 1).
Procedural details are provided in Table 2.
PV isolation was attempted in all patients. Of these,
complete bidirectional conduction block was achieved in
89.1% (88.5% in LARA-1 and 95% in LARA-2; P=0.843), with no
difference in RF duration (5012 minutes vs. 4713 min-
utes; P=0.302) or procedural time (17253 minutes vs.
15351 minutes; P=0.063) between LARA-1 and LARA-2,
respectively. There was a trend to longer ﬂuoroscopy time in
group LARA-1 that did not reach statistical signiﬁcance
(ﬂuoroscopy time [3235 minutes vs. 2213 minutes;
P=0.053]).
During LA appendage pacing, activation mapping conﬁrmed
complete conduction block across the RL in 81.4% of cases in
LARA-1 (Figure 4). Patients with successful RL linear block
were signiﬁcantly older (LARA-1 without block: 4613.7 years
vs. LARA-1 with block: 57.18.8 years; P=0.025). No other
predictor for successful RL block could be identiﬁed.
Overall, the endpoints of the procedure were conﬁrmed
using previously described criteria in 45 and 54 patients of
the LARA-1 (PV isolation and LA roof block) and LARA-2 (PV
isolation) groups, respectively (76.3% vs. 88.5%; P=0.127).
Follow-up
One LARA-1 patient was lost to follow-up because of cancer
and subsequent death. Table 3 summarizes the information at
Table 1. Baseline Characteristics
LARA-1 (n=59) LARA-2 (n=61) P Value Total (n=120)
Age, y 5511 5512 0.857 5511
Males 42 (71.2%) 42 (68.9%) 0.670 84 (70.7)
Hypertension 19 (32.2%) 24 (39.3%) 0.455 43 (35.8%)
Diabetes 2 (3.4%) 4 (6.6%) 0.438 6 (5%)
Previous cardioembolic event 1 (1.7%) 0 0.987 1 (0.8%)
Sports practice 12 (20.3%) 6 (9.8%) 0.117 18 (15%)
Obstructive sleep apnea 3 (5.1%) 5 (8.2%) 0.510 8 (6.7%)
Lone AF 45 (76.3%) 54 (88.5%) 0.127 90 (82.5%)
Structural cardiomyopathy 14 (23.7%) 7 (11.7%) 0.200 21 (17.5%)
Tachycardiomyopathy 1 (1.7%) 0 1 (0.8%)
Ischemic 4 (6.8%) 2 (3.3%) 6 (5%)
Hypertrophic 1 (1.7%) 0 1 (0.8%)
Valvular 6 (10.2%) 1 (1.6%) 7 (5.8%)
Hypertensive 2 (3.4%) 3 (4.9%) 5 (4.2%)
Others 0 1 (1.6%) 1 (0.8%)
CHADS2 ≥1 20 (33.9%) 26 (42.6%) 0.341 46 (38.3%)
CHA2DS2-VASc ≥1 31 (52.5%) 32 (52.4%) 1 63 (52.5%)
AF duration, months 5959 6056 0.902 6057
LA anteroposterior diameter, mm 416 416 0.924 416
LV ejection fraction, % 627 625 0.774 626
LV end-diastolic diameter, mm 524 515 0.108 525
LV end-systolic diameter, mm 335 325 0.534 335
AF indicates atrial ﬁbrillation; LA, left atrium; LV, left ventricle.
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follow-up. After a mean follow-up of 1510 months (median,
12), 35 patients in group LARA-1 (28 with conﬁrmed
conduction block across the RL and 7 without complete RL
block) and 34 in group LARA-2 had no documented arrhyth-
mia recurrence after a single ablation procedure. No statis-
tically signiﬁcant differences were observed in arrhythmia
recurrence between those with or without ablation of the LA
roof (long-rank test, P=0.877; Figure 5A).
In the LARA-1 group, recurrences were the result of AF in
24 patients (40%) and LA ﬂutter in 3 (5.1%). In the LARA-2
group, 27 patients (45%) had AF recurrences, and 5 (8.2%) had
new-onset LA ﬂutter. Univariate analysis identiﬁed AF dura-
tion (hazard ratio [HR], 1.01 [95% conﬁdence interval {CI},
1.002 to 1.012]; P<0.01), as the covariate associated with
arrhythmia recurrence (Table 4).
The 12-month results (Figure 5B) were not inﬂuenced by
achievement of complete block across the RL in LARA-1
patients (HR, 0.96 [95% CI, 0.55 to 1.67]; P=0.880) or by
complete bidirectional block of all PV (HR, 0.986 [95% CI,
0.806 to 1.207]; P=0.843).
Complications
In the LARA-1 group, 1 patient experienced cardiac tampon-
ade, which was successfully drained percutaneously, requiring
no further intervention; another patient had a transient
cerebrovascular ischemic attack, resolved by unfractionated
heparin with no documented lesion on the CT scan and no
sequelae. Two patients in the LARA-2 group had transient
inferior myocardial ischemia, probably related to air embolism
during transseptal catheterization, which was resolved with
intravenous nitroglycerin (100 lg) within a few minutes;
additionally, 1 patient had postprocedural pericarditis without
signiﬁcant pericardial effusion that required nonsteroidal anti-
inﬂammatory therapy for 1 week. Finally, there was 1 mitral
valve rupture in the LARA-1 group, secondary to entrapment
of the circular catheter among the chords; the patient had to
undergo emergent mitral valve repair. No symptomatic
stenosis of the PV was documented by MR at 12 months.
There were no signiﬁcant differences in complication occur-
rence between groups (Table 2).
Second Ablation Procedures
The ablation procedure was repeated 15.711 months after
the index procedure in 27 (22%) patients (14 in LARA-1 and
13 in LARA-2; P=0.92) because of new-onset LA ﬂutter in 6
patients (4 in LARA-1 and 2 in LARA-2; P=0.64) and AF
recurrence in the remaining 21 patients. Overall, the 120
patients included in the study underwent 1.410.57 AF
Table 2. Procedural Data
LARA-1 (n=59) LARA-2 (n=61) P Value Total (n=120)
Procedural time, minutes 17253 15351 0.063 16358
Radiofrequency time, minutes 5012 4713 0.302 4813
Fluoroscopy time, minutes 3235 2213 0.053 2727
PV isolation
Left superior 59 (100%) 61 (100%) 0.285 120 (100%)
Left inferior 57 (96.6%) 57 (93.4%) 0.416 114 (95%)
Right superior 57 (96.6%) 57 (93.4%) 0.478 118 (98.3)
Right inferior 56 (94.91%) 61 (100%) 0.325 114 (95%)
Overall 52 (88.5%) 58 (95.0%) 0.843 106 (89.1%)
Complications 4 (6.7%) 5 (8.5%) 0.390 9 (7.5%)
Stroke 2 (3.4%) 1 (1.6%) 0.97 3 (2.5%)
Coronary ischemia 0 2 (3.3%) 0.164 2 (1.7%)
Pericarditis 0 1 (1.6%) 0.327 1 (0.8%)
Cardiac tamponade 1 (1.7%) 0 0.303 1 (0.8%)
Esophagitis 0 0 — 0
Fever 1 (1.7%) 0 0.303 0
Vascular complications 0 3 (4.9%) 0.087 3 (2.5%)
PV stenosis 0 0 — 0
Mitral valve rupture 1 (1.7%) 0 — 1 (0.8%)
LARA indicates left atrial roof linear ablation; PV, pulmonary vein.
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A1
A2
B1
B2
Figure 4. Color-coded 3D activation map during pacing from the LA appendage in a patient
undergoing a ﬁrst ablation procedure for paroxysmal AF. A, Anteroposterior and postero-
anterior views before linear ablation at the LA roof showing 2 activation fronts at the
posterior wall. B, Anteroposterior and posteroanterior views after linear ablation at the LA
roof showing the caudocranial activation of the LA posterior wall. AF indicates atrial
ﬁbrillation; AP, anteroposterior; LA, left atrium; PA, posteroanterior.
Table 3. Follow-up Data After First Procedure
LARA-1 (n=59) LARA-2 (n=61) P Value Total (n=120)
Follow-up duration, months 139 1611 0.238 1510
Recurrence rate during blanking period 16 (27.1%) 17 (27.9%) 1 33 (27.5%)
Type of recurrence during blanking period
Atrial fibrillation 16 (27.1%) 13 (21.3%) 0.594 28 (23.3%)
Left atrial flutter 0 4 (6.6%) 0.136 4 (3.3%)
Other 0 0 — 0
Recurrence rate during follow-up
>3 months after the procedure 24 (40.7%) 27 (44.3%) 0.832 51 (42.5%)
Complete conduction block across the RL* 20 (42.6%) — —
Incomplete conduction block across the RL* 4 (36.4%) — —
Type of recurrence during follow-up
Atrial fibrillation 21 (35.6%) 22 (36.1%) 1 43 (35.8%)
Left atrial flutter 3 (5.1%) 5 (8.2%) 0.751 8 (6.7%)
Other 0 0 — 0
LARA indicates left atrial roof linear ablation; RL, roof line.
*Comparison between patients in group LARA-1 with complete or incomplete RL conduction block: P=0.655.
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ablation procedures (1.490.646 in LARA-1 and 1.340.476
in LARA-2; P=0.114).
Recovery of PV conduction was observed in a mean of
3.480.749 PV per patient, while no patient had all PVs
isolated. The identiﬁed conduction gaps were located at the
left superior PV in 17 patients (62.9%), left inferior PV in 19
(70.3%), right superior PV in 20 (74.1%), and right inferior PV
in 17 (62.9%). Recovery of conduction across the LA roof line
was observed in 6 patients (42.8%). All 6 patients with LA
ﬂutter showed gaps at the level of the PV responsible for the
reentrant arrhythmia. There were no macroreentries across
the LA roof or mitral-isthmus–dependent ﬂutter. The ablation
strategy of the repeat procedures consisted in PV isolation for
all patients and ablation along the RL to close the gap in those
patients from group LARA-1 with recovered conduction
(Figure 6).
After a follow-up of 15.310.2 months after the last
ablation procedure, 70.8% of the patients of this series
remained arrhythmia free with no difference in arrhythmia-
free survival between groups (Table 5). Thirty-one patients
A B
Figure 5. Accumulated arrhythmia-free survival (Kaplan-Meier) after a single ablation procedure. A, Comparison between the LARA-
1 (solid line) and LARA-2 (dotted line) groups. B, Comparison between the LARA-1 patients that achieved conduction block at the roof
(solid line), the LARA-1 patients that did not achieve conduction block at the roof (slashed line), and the LARA-2 patients (dotted line).
LARA indicates left atrial roof linear ablation.
Table 4. Predictors of All-Cause Recurrence Risk, Uni- and Multivariate Cox Proportional Hazards Models
No Recurrence (n=69) Recurrence (n=51)
Univariate Multivariate
HR (95% CI) P Value HR (95% CI) P Value
Age, y 5412 5710 1.03 (1.00 to 1.06) 0.055
Males 50 (72%) 34 (67%) 0.84 (0.47 to 1.52) 0.842
Hypertension 23 (33%) 20 (39%) 1.38 (0.78 to 2.54) 0.266
Atrial fibrillation duration, months 4839 7472 1.01 (1.00 to 1.01) 0.007 1.01 (1.002 to 1.012) 0.007
Sleep apnea syndrome 3 (4%) 5 (10%) 2.46 (0.97 to 6.28) 0.059
Athlete 8 (12%) 6 (12%) 0.88 (0.37 to 2.10) 0.771
Cardiomyopathy 12 (17%) 9 (18%) 0.98 (0.48 to 2.00) 0.948
LVEF (per % increase) 627 625 1.00 (0.96 to 1.05) 0.961
LA diameter 415 416 1.01 (0.96 to 1.07) 0.599
CHADS2 score 3 (4%) 2 (4%) 1.23 (0.30 to 5.09) 0.777
CHA2DS2-VASc score 31 (45%) 29 (57%) 1.48 (0.84 to 2.62) 0.178
LARA-1 (roof line) 34 (49%) 24 (47%) 1.04 (0.60 to 1.81) 0.880
CI indicates conﬁdence interval; HR, hazard ratio; LA, left atrium; LARA, left atrial roof linear ablation; LVEF, left ventricular ejection fraction.
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had AF recurrence (14 in group LARA-1 and 17 in LARA-2;
P=0.079).
Discussion
The main ﬁnding of this prospective, randomized study is that
linear ablation at the LA roof does not improve 12-month
success after PV isolation for paroxysmal AF, independently of
the achievement of bidirectional block. Furthermore, the
incidence of macroreentrant arrhythmias after a single
ablation in this type of patient did not differ signiﬁcantly
between groups.
Linear Ablation for AF Ablation
Currently, circumferential PV ablation with veriﬁcation of
electrical disconnection, associated or not to additional linear
lesions, probably represents the most accepted ablation
strategy in PAF.1–4 However, despite the various ablation
strategies available, single-procedure efﬁcacy is still unsatis-
factory: 60% to 80% in PAF, with 40% to 50% of patients
requiring a second procedure to achieve long-term freedom
from AF.16–18 Because the efﬁcacy of AF ablation seems to be
related to the extent of ablated tissue,19 there has been a
trend toward more-extensive ablation. The creation of addi-
tional lesions on top of the isolation of the PV has been
proposed in an attempt to obtain success comparable to that
obtained with surgical linear ablation lesions. Still, the existing
evidence provides contradictory information about the use-
fulness, number, and location of linear lesions.
The role of additional lines in cases of PAF is particularly
unclear. It has been suggested that ablation lines along the
roof of the LA and mitral isthmus may improve clinical
outcomes in PAF.7,9,20 Conversely, the exclusion of the LA
posterior wall has no effect on the incidence of AF
recurrences after circumferential PV ablation, in a randomized
trial of 120 patients (60% in PAF).13 Finally, a randomized,
prospective trial comparing segmental PV isolation and
circumferential PV ablation plus linear ablation at the LA roof
and MI showed that signiﬁcantly more patients had LA ﬂutter
in the linear ablation group.21
To our knowledge, only 2 other randomized studies have
evaluated the effect of linear ablation at the LA roof, with
conﬂicting results.9,22 Hocini et al.9 randomized 90 patients
A B
Figure 6. Conﬁrmation of persistent conduction block at the LA roof in a patient undergoing a repeat
ablation procedure for recurrent paroxysmal AF. A, Color-coded 3D activation map showing a caudocranial
activation of the posterior wall. B, Double potential at the roof line (112 ms between spikes). AF indicates
atrial ﬁbrillation; LA, left atrium.
Table 5. Follow-up Data After Last Procedure
LARA-1 (n=59) LARA-2 (n=61) P Value Total (n=120)
Follow-up duration, months 14.068.764 16.3911.33 0.230 15.2510.17
Recurrence rate during follow-up
>3 months after the procedure 15 (25.4%) 19 (31.1%) 0.622 34 (28.3%)
Type of recurrence during follow-up
Atrial fibrillation 14 (23.7%) 17 (27.9%) 0.755 31 (25.8%)
Left atrial flutter 1 (0.02%) 3 (0.05%) 0.635 4 (0.03%)
Other 0 0 — 0
LARA indicates left atrial roof linear ablation.
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to PV isolation with or without LA roof linear ablation (1:1
ratio). In their study, additional rooﬂine ablation was associ-
ated with 87% of patients being arrhythmia free without
antiarrhythmics, compared with 69% undergoing PV isolation
alone, after a follow-up of 154 months.
More recently, Mun et al.22 randomized 156 patients into
3 different groups (1:1:1 ratio): PV isolation alone, PV isolation
together with LARA, and PV isolation with the “box lesion”
(RL+posterior line); the ﬁndings did not conﬁrm those
described by Hocini et al.,9 because the addition of the LA
rooﬂine did not improve the clinical outcome at 156 months
after the index procedure.
In our randomized study, the deployment of an ablation line
at the LA roof did not improve the arrhythmia recurrence rate.
The reason for the disparate ﬁndings may be related to
differences in PV isolation techniques, rather than to the LARA
itself. Wider antral PV isolation is likely to reduce the critical
mass for maintenance of AF more than the more ostial
approach performed by Hocini et al.9,23
Linear Ablation to Prevent LA Macroreentrant
Arrhythmias
Linear ablation in addition to PV isolation was initially
suggested as a means to prevent atrial tachycardia after
circumferential PV ablation.8 However, previous results from
our group13 and others21 have not shown any beneﬁt from
additional linear lesions in terms of the risk of LA ﬂutter. The
present study also supports the idea that additional ablation
lines may not be necessary in patients with PAF to prevent
post-AF ablation macroreentrant arrhythmias. This is most
probably because the predominant underlying mechanism of
AF in these patients is mainly focal triggers; the substrate
does not play a relevant role. Favoring this theory, all second
procedures to treat LA ﬂutter after the index ablation showed
a reentrant circuit using gaps located at the previous PV
encircling lesions or at the LARA, in accord with other
series.13,24 The difﬁculty in achieving continuity around
ipsilateral PVs has already been described, especially at the
septal aspect and the area between the LA appendage and
left superior PV.25 Furthermore, it has been widely shown that
macroreentrant arrhythmias during follow-up are frequently
related to gaps in previous linear lesions.6,10,12,21,24,26–29
Therefore, if additional linear lesions are applied, line
completeness should be demonstrated by mapping or pacing
maneuvers.
Clinical Implications
The results of the study clearly show that ablation of the LA
roof in addition to PV isolation does not add clinical beneﬁt,
compared with PV isolation alone in patients with PAF.
Although the total procedural time and RF delivery duration
did not increase signiﬁcantly when the ablation line was
added, care must be taken to avoid potential risks, such as
perforation or esophageal damage. There was also a trend to
longer ﬂuoroscopy time in the LARA-1 group, although it did
not reach statistical signiﬁcance, probably because of lack of
statistical power.
On the other hand, linear lesions may promote LA
macroreentrant arrhythmias secondary to conduction recov-
ery along the line. Therefore, the results of this randomized
study further support the thesis that linear ablation at the LA
roof is not necessary as a predeﬁned lesion set to treat PAF.
Study Limitations
The study was planned to detect an absolute reduction of 20%
in the proportion of arrhythmia-free patients assuming that
55% of patients would be recurrence free at 6 months, based
on the earlier experience of our group. Yet, the recurrence-
free survival at 6 months was closer to 80. This could reduce
the power to detect differences among groups within the
study. However, the same number of patients were arrhyth-
mia free in both groups; consequently, the formal comparison
is far from the 5% signiﬁcance level and the adjusted HR for
arrhythmia recurrence was close to 1. Therefore, the lack of
statistical signiﬁcance may not be attributable to low
statistical power. On the other hand, the lack of the sample
size was not calculated to take into account possible
subgroup analyses; therefore, the absence of identiﬁable
predictors of successful RL block could be secondary to lack
of statistical power.
The study cannot exclude that the LA roof linear ablation
may have some effect in individual AF cases because the
effect of this ablation was evaluated as part of a predeﬁned
lesion set performed in all patients. Tailored approaches for
AF ablation have been proposed.30–32 Finally, arrhythmia
recurrence was detected by routine 48-hour Holter monitoring
and ECG recording when symptoms occurred between
scheduled visits. It is likely that some arrhythmia recurrences
may have escaped detection in asymptomatic patients.
However, this limitation affects both ablation groups equally
and therefore should not affect the study conclusions.
Moreover, this pragmatic approach has been taken in many
other published studies.7,9,11,33–36
Conclusion
This double-blinded, prospective, randomized study shows
that there is not sufﬁcient evidence to suggest that linear
ablation at the roof of the LA improves the mid-term results of
PV isolation for the treatment of PFA, independently of the
achievement of bidirectional block.
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